OPRX logo

OptimizeRx Corporation (OPRX)

$7.34

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on OPRX

Market cap

$138255880

EPS

0.26

P/E ratio

34.5

Price to sales

1.58

Dividend yield

--

Beta

1.19707

Price on OPRX

Previous close

$8.87

Today's open

$8.43

Day's range

$7.22 - $8.69

52 week range

$4.54 - $16.37

Profile about OPRX

CEO

Stephen L. Silvestro

Employees

133

Headquarters

Waltham, MA

Exchange

NASDAQ Capital Market

Shares outstanding

18835951

Issue type

Common Stock

OPRX industries and sectors

Healthcare

Healthcare Providers & Services

News on OPRX

OptimizeRx to Participate in the 15th Annual ROTH Technology Conference

WALTHAM, Mass., Nov. 16, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients at critical decision points, today announced that management will participate in the 15th Annual ROTH Technology Conference taking place on Wednesday, November 18, 2026, in New York, NY.

news source

GlobeNewsWire • 18 hours ago

news preview

These Analysts Cut Their Forecasts On OptimizeRx After Q3 Results

OptimizeRx Corporation (NASDAQ:OPRX) reported upbeat earnings for the third quarter, but lowered its sales guidance on Wednesday.

news source

Benzinga • Nov 12, 2026

news preview

What OptimizeRx (OPRX) Said on Its Q3 Earnings Call

OptimizeRx NASDAQ: OPRX lowered its 2026 revenue outlook after third-quarter sales fell 17%, even as cost reductions and a favorable product mix helped the healthcare marketing technology company increase profitability.

news source

MarketBeat • Nov 12, 2026

news preview

OptimizeRx Corporation (OPRX) Q3 2026 Earnings Call Transcript

OptimizeRx Corporation (OPRX) Q3 2026 Earnings Call Transcript

news source

Seeking Alpha • Nov 12, 2026

news preview

OptimizeRx Reports Third Quarter 2026 Financial Results and Updates Fiscal Year 2026 Guidance

WALTHAM, Mass., Nov. 11, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced results for the three months ended September 30, 2026.

news source

GlobeNewsWire • Nov 11, 2026

news preview

OptimizeRx Corp. (OPRX) Q3 Earnings and Revenues Beat Estimates

OptimizeRx Corp. (OPRX) came out with quarterly earnings of $0.2 per share, beating the Zacks Consensus Estimate of $0.18 per share. This compares to earnings of $0.2 per share a year ago.

news source

Zacks Investment Research • Nov 11, 2026

news preview

OptimizeRx Sets Third Quarter 2026 Conference Call for November 11, 2026 at 4:30 p.m. ET

WALTHAM, Mass., Oct. 28, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients at critical decision points, will hold a conference call on Wednesday, November 11, 2026, at 4:30 p.m.

news source

GlobeNewsWire • Oct 28, 2026

news preview

OptimizeRx and PulsePoint Partner to Connect HCP Media Across the Funnel

Latest DSP integration expands buyer access to OptimizeRx point of care inventory through existing programmatic workflows Latest DSP integration expands buyer access to OptimizeRx point of care inventory through existing programmatic workflows

news source

GlobeNewsWire • Oct 27, 2026

news preview

OptimizeRx Brings Net New Authenticated HCP Reach to The Trade Desk Through OpenPath

WALTHAM, Mass., Sept. 22, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients at critical decision points, today announced an integration with OpenPath, The Trade Desk's supply path optimization solution, making OptimizeRx's authenticated point of care inventory available directly to advertisers using The Trade Desk's leading, data-driven demand side platform (DSP).

news source

GlobeNewsWire • Sep 22, 2026

news preview

OptimizeRx: Gross Margin Gains And Improved Long-Term Outlook

OptimizeRx is upgraded to 'Buy' due to an improved 2027 growth outlook and an attractive valuation. Q2 2026 saw gross margin rise to 76.5%, marking five consecutive quarters of gains amid a strategic shift to higher-margin offerings. OPRX reaffirmed 2026 guidance: revenue of $95M–$100M and adjusted EBITDA of $21M–$25M.

news source

Seeking Alpha • Sep 18, 2026

news preview

¹ Disclosures

Get started with M1

Invest in OptimizeRx Corporation

Open an M1 investment account to buy and sell OptimizeRx Corporation commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in OPRX on M1